Picture of Hamlet BioPharma AB logo

HAMLET B — Hamlet BioPharma AB Cashflow Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Annual cashflow statement for Hamlet BioPharma AB, fiscal year end - June 30th, SEK millions except per share, conversion factor applied.

2022
June 30th
2023
June 30th
2024
June 30th
2025
June 30th
2026
June 30th
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSPRESS
Standards:
SAS
SAS
SAS
SAS
SAS
Status:FinalFinalFinalFinalPreliminary
Net Income/Starting Line-17.2-20.4-41.8-54.7-55.6
Non-Cash Items0.0090.4997.8310.510.2
Other Non-Cash Items
Changes in Working Capital-3.130.329-2.02-38.81.09
Change in Accounts Receivable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-20.3-19.6-36-83-44.3
Capital Expenditures—-9.97-0.278-0.025-0.353
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Cash from Investing Activities—-9.97-0.278-0.025-0.353
Financing Cash Flow Items-3.66-0.132-0.779-0.277-0.15
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities52.58.374126.539
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash32.1-21.24.71-12.3-5.67